Equillium, Inc. (NASDAQ:EQ) Receives $7.67 Consensus Target Price from Analysts

Shares of Equillium, Inc. (NASDAQ:EQ) have earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $7.6667.

A number of brokerages have recently issued reports on EQ. Raymond James Financial began coverage on Equillium in a research note on Monday, April 13th. They issued a “strong-buy” rating and a $6.00 price objective on the stock. Stifel Nicolaus began coverage on Equillium in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price objective on the stock. Cantor Fitzgerald began coverage on Equillium in a research note on Tuesday, April 7th. They issued an “overweight” rating and a $10.00 price objective on the stock. B. Riley Financial began coverage on Equillium in a research note on Thursday, April 16th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, Roth Mkm reissued a “buy” rating and issued a $12.00 price objective on shares of Equillium in a research note on Friday, April 17th.

Insider Activity

In other news, COO Christine Zedelmayer sold 185,937 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $1.76, for a total value of $327,249.12. Following the transaction, the chief operating officer directly owned 191,444 shares of the company’s stock, valued at $336,941.44. The trade was a 49.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 487,468 shares of company stock valued at $990,467. 17.84% of the stock is owned by insiders.

Institutional Trading of Equillium

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EQ. Aberdeen Group plc bought a new stake in Equillium in the 3rd quarter valued at about $543,000. Vanguard Group Inc. increased its position in Equillium by 59.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock valued at $1,879,000 after buying an additional 489,855 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in Equillium in the 3rd quarter valued at about $99,000. Two Sigma Investments LP bought a new stake in Equillium in the 3rd quarter valued at about $190,000. Finally, ADAR1 Capital Management LLC bought a new stake in Equillium in the 3rd quarter valued at about $7,951,000. 27.05% of the stock is owned by institutional investors.

Equillium Trading Down 1.4%

Shares of EQ opened at $2.11 on Friday. The company has a market capitalization of $133.42 million, a PE ratio of -4.22 and a beta of 1.67. Equillium has a 12 month low of $0.27 and a 12 month high of $2.70. The stock’s 50-day moving average price is $2.00 and its two-hundred day moving average price is $1.53.

Equillium (NASDAQ:EQ) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. Equities research analysts predict that Equillium will post -0.21 EPS for the current fiscal year.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.